NCT02736721View on ClinicalTrials.gov

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Myelogenous Leukemia, Chronic
Interventions
DRUG

Peginterferon alfa-2a

Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.

Trial Locations (5)

35043

Marburg

55101

Mainz

68167

Mannheim

72076

Tübingen

79106

Freiburg im Breisgau

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02736721 - Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML) | Biotech Hunter | Biotech Hunter